On December 18, 2023, Neurogene Inc. closed the transaction. The company has now issued 36,934,089 common shares and 23,964,846 pre-funded warrants for gross proceeds of approximately $95 million. At the closing, the securities were converted into shares of company's common Stock and $0.000001 pre-funded warrants at a rate of 0.0756 shares of common stock per share, and 0.0756 $0.000001 pre-funded warrants for each company's prefunded warrant.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.64 USD | -5.72% | -6.61% | +58.10% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
790.3 USD | -0.80% | +2.03% | 117B | ||
30.64 USD | -5.72% | -6.61% | 394M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.10% | 394M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+45.09% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neurogene Inc. announced that it has received $95 million in funding from a group of investors